NSRX Stock Nasus Pharma (NSRX, $4) gained +37.46% in one month, becoming one of the top market winners among penny stocks
at Tickeron.com
Loading...
A.I.dvisor analyzed 21 other stocks in the Pharmaceuticals: Major Industry for the month ending August 21, 2026, and discovered that of them (7) exhibited an Uptrend while of them (2) exhibited a Downtrend.
NSRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 09, 2026
NSRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 8 of 8 cases where NSRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where NSRX advanced for three days, in 31 of 36 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 21 of 21 cases where NSRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for NSRX moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 similar instances where the indicator moved out of overbought territory. In 2 of the 3 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NSRX as a result. In 22 of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NSRX turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In 11 of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NSRX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating for company is 33 (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.627) is normal, around the industry mean (18.892). NSRX has a moderately low P/E Ratio (0.000) as compared to the industry average of (31.670). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.721). NSRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). NSRX's P/S Ratio (0.000) is slightly lower than the industry average of (3.991).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. NSRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.